iSpecimen Inc. Announces Acquisition of Foldlab AI Assets for $4.5M

What Happened
iSpecimen Inc. announced on September 4, 2026 that it entered into an Asset Purchase Agreement to acquire certain AI software, models, source code, data rights and related intellectual property from Foldlab AI Ltd., including the "Disease-Associated Protein Discovery AI Agent" and the "Disease Trend Prediction and Monitoring AI Model." The aggregate purchase price is $4,500,000: $2,000,000 in cash and $2,500,000 in shares of iSpecimen common stock. The company said it will file a proxy statement and seek stockholder approval for the stock issuance.

Key Details

• Total purchase price: $4,500,000 (Cash $2,000,000 + Stock $2,500,000).
• Cash payment structure: $750,000 payable at closing; two milestone payments of $625,000 each payable only upon successful delivery, testing and acceptance of the two AI products.
• Stock consideration: Number of shares = $2,500,000 divided by the 10‑day VWAP ending the trading day before closing; shares issued under private-placement exemption and deposited into escrow.
• Escrow/lock-up: Stock consideration will be held in escrow with a five‑year lock-up (no leak‑out) and subject to a voting‑rights agreement granting iSpecimen an irrevocable proxy on certain corporate matters.
• Closing conditions include buyer stockholder approval (Nasdaq Listing Rule 5635(a)), Nasdaq confirmation of listing, availability of the private-placement exemption, regulatory/third‑party consents, delivery of seller disclosures, and no material adverse effect on the assets.

Why It Matters
This is an asset acquisition (not a merger) that adds targeted AI models and related IP to iSpecimen’s capabilities, paid with a mix of cash and equity. The stock portion requires shareholder approval and will be escrowed and restricted for five years, limiting immediate dilution or market selling of those shares. Cash milestone payments depend on objective acceptance testing, which could delay or prevent part of the cash outlay if the products fail to meet the criteria. Investors should watch for the company’s proxy filing, the timing of stockholder approval, Nasdaq confirmation of listing, and any updates on delivery/acceptance of the AI products.